Elicio Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Elicio Therapeutics details its financial performance for 2024 and highlights the expected Q3 2025 interim analysis of its Phase 2 AMPLIFY-7P trial.
NASDAQ
10-K/A: Elicio Therapeutics Files Amended 10-K to Include Omitted Information and Updated Certifications
Elicio Therapeutics has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and updated certifications from its principal executive and financial officers.
NASDAQ
Elicio Therapeutics has amended its non-employee director compensation policy, outlining cash retainers, committee chair and member fees, and equity awards for board service.